Pancreatic Adenocarcinoma

Oncology
11
Pipeline Programs
9
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
7
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 11 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

AT
Actuate TherapeuticsFORT WORTH, TX
3 programs
1
2
9-ING-41Phase 21 trial
FOLFIRNINOXPhase 21 trial
RetifanlimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06896188Recruiting12Est. Dec 2028
NCT05239182Terminated7Est. Feb 2024
NCT05077800Active Not RecruitingEst. Jul 2026
Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
2
CapecitabinePhase 21 trial
FluorouracilPhase 21 trial
Active Trials
NCT04539808Active Not Recruiting42Est. Jan 2027
NCT02427841Completed20Est. Dec 2022
Pfizer
PfizerNEW YORK, NY
1 program
1
FOLFIRIPhase 21 trial
Active Trials
NCT01543412Completed50Est. Dec 2011
Verona Pharma
Verona PharmaUK - London
1 program
1
Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic AcidPhase 21 trial
Active Trials
NCT03528785Unknown67Est. Nov 2022
Ipsen
IpsenChina - Tianjin
1 program
1
Liposomal IrinotecanPhase 21 trial
Active Trials
NCT03483038Active Not Recruiting45Est. Dec 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DurvalumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03245541Active Not Recruiting18Est. Sep 2026
Candel Therapeutics
1 program
1
AdV-tkPhase 11 trial
Active Trials
NCT00638612CompletedEst. Jun 2015
Gossamer Bio
Gossamer BioCA - San Diego
1 program
1
GB1275Phase 1
Olympus
OlympusPA - Center Valley
2 programs
Spectroscopy deviceN/A1 trial
Tumor markersN/A1 trial
Active Trials
NCT01753479Completed445Est. Jun 2016
NCT01699698Completed105

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Actuate TherapeuticsFOLFIRNINOX
Actuate Therapeutics9-ING-41
Knight TherapeuticsCapecitabine
IpsenLiposomal Irinotecan
Verona PharmaIrinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
Knight TherapeuticsFluorouracil
PfizerFOLFIRI
AstraZenecaDurvalumab
Actuate TherapeuticsRetifanlimab
Candel TherapeuticsAdV-tk
OlympusSpectroscopy device
OlympusTumor markers

Clinical Trials (12)

Total enrollment: 811 patients across 12 trials

NCT05077800Actuate TherapeuticsFOLFIRNINOX

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Start: Mar 2022Est. completion: Jul 2026
Phase 2Active Not Recruiting
NCT05239182Actuate Therapeutics9-ING-41

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Start: Jan 2022Est. completion: Feb 20247 patients
Phase 2Terminated
NCT04539808Knight TherapeuticsCapecitabine

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Start: May 2021Est. completion: Jan 202742 patients
Phase 2Active Not Recruiting
NCT03483038IpsenLiposomal Irinotecan

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Start: Dec 2018Est. completion: Dec 202645 patients
Phase 2Active Not Recruiting
NCT03528785Verona PharmaIrinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid

A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer

Start: Mar 2018Est. completion: Nov 202267 patients
Phase 2Unknown
NCT02427841Knight TherapeuticsFluorouracil

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Start: Jan 2016Est. completion: Dec 202220 patients
Phase 2Completed
NCT01543412PfizerFOLFIRI

Second Line Chemotherapy for Advanced Pancreatic Cancer

Start: Jan 2010Est. completion: Dec 201150 patients
Phase 2Completed
NCT03245541AstraZenecaDurvalumab

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Start: Aug 2020Est. completion: Sep 202618 patients
Phase 1/2Active Not Recruiting
NCT06896188Actuate TherapeuticsRetifanlimab

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Start: Sep 2025Est. completion: Dec 202812 patients
Phase 1Recruiting
NCT00638612Candel TherapeuticsAdV-tk

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Start: Aug 2008Est. completion: Jun 2015
Phase 1Completed
NCT01753479OlympusSpectroscopy device

Spectroscopy From Duodenum

Start: Jan 2013Est. completion: Jun 2016445 patients
N/ACompleted
NCT01699698OlympusTumor markers

Pancreatic Juice Diagnosis From Duodenum

Start: Oct 2012105 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 811 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)